vs

Side-by-side financial comparison of Emerson Electric (EMR) and Lam Research (LRCX). Click either name above to swap in a different company.

Lam Research is the larger business by last-quarter revenue ($5.8B vs $4.6B, roughly 1.3× Emerson Electric). Lam Research runs the higher net margin — 31.2% vs 13.5%, a 17.7% gap on every dollar of revenue. On growth, Lam Research posted the faster year-over-year revenue change (23.8% vs 3.0%). Over the past eight quarters, Lam Research's revenue compounded faster (22.8% CAGR vs -0.6%).

Emerson Electric Co. is an American multinational corporation headquartered in St. Louis, Missouri. The Fortune 500 company delivers a range of engineering services, manufactures industrial automation equipment, climate control systems, and precision measurement instruments, and provides software engineering for industrial, commercial, and consumer markets.

Lam Research Corporation is an American supplier of wafer-fabrication equipment and related services to the semiconductor industry. Its products are used primarily in front-end wafer processing, which involves the steps that create the active components of semiconductor devices and their wiring (interconnects). The company also builds equipment for back-end wafer-level packaging (WLP) and for related manufacturing markets such as for microelectromechanical systems (MEMS).

EMR vs LRCX — Head-to-Head

Bigger by revenue
LRCX
LRCX
1.3× larger
LRCX
$5.8B
$4.6B
EMR
Growing faster (revenue YoY)
LRCX
LRCX
+20.8% gap
LRCX
23.8%
3.0%
EMR
Higher net margin
LRCX
LRCX
17.7% more per $
LRCX
31.2%
13.5%
EMR
Faster 2-yr revenue CAGR
LRCX
LRCX
Annualised
LRCX
22.8%
-0.6%
EMR

Income Statement — Q3 FY2026 vs Q3 FY2026

Metric
EMR
EMR
LRCX
LRCX
Revenue
$4.6B
$5.8B
Net Profit
$618.0M
$1.8B
Gross Margin
53.1%
49.8%
Operating Margin
35.0%
Net Margin
13.5%
31.2%
Revenue YoY
3.0%
23.8%
Net Profit YoY
43.7%
37.2%
EPS (diluted)
$1.10
$1.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EMR
EMR
LRCX
LRCX
Q2 26
$4.6B
Q1 26
$4.3B
$5.8B
Q4 25
$4.3B
$5.3B
Q3 25
$4.9B
$5.3B
Q2 25
$4.6B
$5.2B
Q1 25
$4.4B
$4.7B
Q4 24
$4.2B
$4.4B
Q3 24
$4.6B
$4.2B
Net Profit
EMR
EMR
LRCX
LRCX
Q2 26
$618.0M
Q1 26
$606.0M
$1.8B
Q4 25
$605.0M
$1.6B
Q3 25
$637.0M
$1.6B
Q2 25
$586.0M
$1.7B
Q1 25
$485.0M
$1.3B
Q4 24
$585.0M
$1.2B
Q3 24
$996.0M
$1.1B
Gross Margin
EMR
EMR
LRCX
LRCX
Q2 26
53.1%
Q1 26
53.2%
49.8%
Q4 25
53.2%
49.6%
Q3 25
51.9%
50.4%
Q2 25
52.6%
50.1%
Q1 25
53.5%
49.0%
Q4 24
53.5%
47.4%
Q3 24
51.3%
48.0%
Operating Margin
EMR
EMR
LRCX
LRCX
Q2 26
Q1 26
35.0%
Q4 25
17.8%
33.9%
Q3 25
16.4%
34.4%
Q2 25
16.1%
33.7%
Q1 25
14.2%
33.1%
Q4 24
18.6%
30.5%
Q3 24
14.7%
30.3%
Net Margin
EMR
EMR
LRCX
LRCX
Q2 26
13.5%
Q1 26
13.9%
31.2%
Q4 25
13.9%
29.8%
Q3 25
13.1%
29.5%
Q2 25
12.9%
33.3%
Q1 25
10.9%
28.2%
Q4 24
14.0%
27.2%
Q3 24
21.6%
26.8%
EPS (diluted)
EMR
EMR
LRCX
LRCX
Q2 26
$1.10
Q1 26
$1.07
$1.45
Q4 25
$1.07
$1.26
Q3 25
$1.12
$1.24
Q2 25
$1.04
$1.34
Q1 25
$0.86
$1.03
Q4 24
$1.02
$0.92
Q3 24
$1.74
$0.86

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EMR
EMR
LRCX
LRCX
Cash + ST InvestmentsLiquidity on hand
$1.8B
$4.8B
Total DebtLower is stronger
$13.4B
Stockholders' EquityBook value
$20.3B
Total Assets
$42.1B
$20.8B
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EMR
EMR
LRCX
LRCX
Q2 26
$1.8B
Q1 26
$1.7B
$4.8B
Q4 25
$6.2B
Q3 25
$6.7B
Q2 25
$6.4B
Q1 25
$5.5B
Q4 24
$5.7B
Q3 24
$6.1B
Total Debt
EMR
EMR
LRCX
LRCX
Q2 26
$13.4B
Q1 26
$13.4B
Q4 25
$7.6B
$3.7B
Q3 25
$8.9B
$3.7B
Q2 25
$8.3B
$3.7B
Q1 25
$8.2B
$3.7B
Q4 24
$6.6B
$4.5B
Q3 24
$7.7B
$4.5B
Stockholders' Equity
EMR
EMR
LRCX
LRCX
Q2 26
$20.3B
Q1 26
$20.3B
Q4 25
$20.3B
$10.1B
Q3 25
$20.3B
$10.2B
Q2 25
$19.9B
$9.9B
Q1 25
$19.2B
$9.5B
Q4 24
$20.5B
$8.8B
Q3 24
$21.6B
$8.5B
Total Assets
EMR
EMR
LRCX
LRCX
Q2 26
$42.1B
Q1 26
$41.9B
$20.8B
Q4 25
$41.9B
$21.4B
Q3 25
$42.0B
$21.9B
Q2 25
$42.5B
$21.3B
Q1 25
$42.0B
$20.0B
Q4 24
$42.6B
$19.8B
Q3 24
$44.2B
$19.5B
Debt / Equity
EMR
EMR
LRCX
LRCX
Q2 26
0.66×
Q1 26
0.66×
Q4 25
0.37×
0.37×
Q3 25
0.44×
0.37×
Q2 25
0.42×
0.38×
Q1 25
0.42×
0.39×
Q4 24
0.32×
0.51×
Q3 24
0.36×
0.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EMR
EMR
LRCX
LRCX
Operating Cash FlowLast quarter
$1.1B
Free Cash FlowOCF − Capex
$694.0M
FCF MarginFCF / Revenue
15.2%
Capex IntensityCapex / Revenue
4.0%
5.7%
Cash ConversionOCF / Net Profit
0.63×
TTM Free Cash FlowTrailing 4 quarters
$4.6B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EMR
EMR
LRCX
LRCX
Q2 26
Q1 26
$1.1B
Q4 25
$699.0M
$1.5B
Q3 25
$3.1B
$1.8B
Q2 25
$1.1B
$2.6B
Q1 25
$241.0M
$1.3B
Q4 24
$777.0M
$741.9M
Q3 24
$3.3B
$1.6B
Free Cash Flow
EMR
EMR
LRCX
LRCX
Q2 26
$694.0M
Q1 26
$602.0M
Q4 25
$602.0M
$1.2B
Q3 25
$2.7B
$1.6B
Q2 25
$977.0M
$2.4B
Q1 25
$154.0M
$1.0B
Q4 24
$694.0M
$553.6M
Q3 24
$2.9B
$1.5B
FCF Margin
EMR
EMR
LRCX
LRCX
Q2 26
15.2%
Q1 26
13.9%
Q4 25
13.9%
22.8%
Q3 25
54.9%
29.9%
Q2 25
21.5%
46.1%
Q1 25
3.5%
21.6%
Q4 24
16.6%
12.7%
Q3 24
63.1%
35.0%
Capex Intensity
EMR
EMR
LRCX
LRCX
Q2 26
4.0%
Q1 26
2.2%
5.7%
Q4 25
2.2%
4.9%
Q3 25
8.9%
3.5%
Q2 25
2.0%
3.3%
Q1 25
2.0%
6.1%
Q4 24
2.0%
4.3%
Q3 24
9.1%
2.7%
Cash Conversion
EMR
EMR
LRCX
LRCX
Q2 26
Q1 26
0.63×
Q4 25
1.16×
0.93×
Q3 25
4.86×
1.13×
Q2 25
1.83×
1.48×
Q1 25
0.50×
0.98×
Q4 24
1.33×
0.62×
Q3 24
3.35×
1.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons